Trimetazidine SR Pellets are pharmaceutical-grade sustained-release multiparticulate pellets containing Trimetazidine as the active pharmaceutical ingredient. They are designed for oral formulation applications where a controlled and prolonged release profile is required from individual pellet units.
Trimetazidine is commonly supplied as Trimetazidine Dihydrochloride, identified by CAS Number 13171-25-0, molecular formula C₁₄H₂₂Cl₂N₂O₃, and molecular weight 339.26 g/mol. The dihydrochloride form is the pharmaceutical salt used in established pharmaceutical formulations.
The pellet format provides a multiparticulate platform in which active loading, pellet size, physical characteristics and release-controlling properties can be managed according to the intended formulation. Sustained-release performance may be achieved through the pellet composition, matrix system, functional coating or a combination of formulation technologies.
Commercial pharmaceutical pellet portfolios document Trimetazidine SR Pellets at 35% w/w, with another commercial product portfolio also listing 35% and 37.5% formats. Therefore, 35% w/w is a documented commercial Trimetazidine SR pellet strength. The strength displayed on the SDP website should correspond to the current SDP product specification or COA.
Trimetazidine Sustained-Release Pellets are developed as multiple individual pellet units rather than a single-unit formulation. This multiparticulate structure provides flexibility during formulation development and can support consistent processing during downstream manufacturing.
The sustained-release characteristics of the pellet system can depend on the composition of the pellet core and, where applicable, the use of a release-controlling functional layer. Important formulation parameters can include Trimetazidine active loading, pellet size, polymer selection, polymer concentration, coating weight gain, coating thickness, coating uniformity, pellet porosity and surface characteristics.
The individual pellet units can be engineered to provide defined physical characteristics and a controlled release profile suitable for the intended oral formulation.
Trimetazidine 35% SR Pellets are a commercially documented sustained-release pellet format. Commercial pharmaceutical pellet portfolios specifically list Trimetazidine SR Pellets at 35% w/w, while another commercial portfolio lists 35% and 37.5% formats.
For the SDP website:
Available Strength: 35% w/w
should be displayed when this strength is confirmed by the applicable SDP product specification.
Active loading is an important characteristic of Trimetazidine SR Pellets because it defines the amount of active ingredient contained within a specified pellet mass. It can also influence the proportion of excipients, pellet structure, manufacturing parameters, physical properties and release performance.
The multiparticulate structure of Trimetazidine SR Pellets provides formulation flexibility for oral pharmaceutical applications. Each pellet functions as an individual unit within the overall formulation, allowing developers to evaluate active distribution and release characteristics across the pellet population.
Trimetazidine SR Pellets can be considered for:
The final suitability depends on the intended formulation design and applicable finished-product specification.
Capsule filling is an important application for pharmaceutical multiparticulate pellets. Trimetazidine SR Pellets can be developed with suitable particle-size distribution, density, flow characteristics and mechanical strength to support capsule-filling processes.
Consistent pellet characteristics are important for reproducible processing. Variations in pellet size, density, friability or active distribution can affect filling behavior and finished-product uniformity.
Important physical parameters may include:
These characteristics should be controlled according to the applicable finished-product specification.
The release profile of Trimetazidine SR Pellets depends on the formulation and manufacturing design. Important variables can include:
A sustained-release pellet system does not have one universal dissolution profile applicable to every formulation. The appropriate dissolution method and acceptance criteria should therefore be established for the specific finished product.
Active loading is a key quality attribute for Trimetazidine SR Pellets. The intended concentration of Trimetazidine should remain consistent throughout the manufactured pellet batch.
Content uniformity is particularly important in multiparticulate formulations because the active ingredient should be distributed consistently within the pellet population. Appropriate process controls and analytical testing can help evaluate active distribution and batch consistency.
The pharmaceutical API specification should also be distinguished from the finished-pellet specification. API assay, moisture, impurity and other pharmacopoeial requirements apply to the starting pharmaceutical ingredient and should not automatically be transferred to a finished 35% pellet specification.
High-quality Trimetazidine Pharmaceutical Pellets can be evaluated through chemical, physical and performance-related characteristics.
Chemical evaluation can include:
Physical evaluation can include:
Performance evaluation can include:
The final acceptance criteria should be based on the applicable finished-product specification.
Trimetazidine SR Pellets provide a flexible multiparticulate platform for sustained-release formulation development. Formulation developers can evaluate active loading, pellet size, core composition, functional coating characteristics and release performance according to the intended formulation requirements.
The pellet format can also support process optimization and scale-up by providing defined physical characteristics for downstream manufacturing operations.
For pharmaceutical manufacturers developing oral multiparticulate formulations, consistent pellet characteristics can help support reproducible processing, capsule filling and finished-product quality.
Trimetazidine SR Pellets from Swapnroop are positioned as pharmaceutical-grade multiparticulate pellets for sustained-release formulation and bulk pharmaceutical applications.
Key product advantages include:
As a Trimetazidine SR Pellets Manufacturer and Supplier in India, Swapnroop can position Trimetazidine sustained-release pellets for pharmaceutical formulation development, multiparticulate applications, capsule filling and bulk pharmaceutical requirements, subject to the applicable product specification.
The product can be developed around relevant formulation parameters including active loading, pellet size, physical characteristics, active distribution and sustained-release performance.
Customers searching for Trimetazidine SR Pellets Manufacturer in India, Trimetazidine SR Pellets Supplier in India, Trimetazidine 35% SR Pellets, Trimetazidine Pharmaceutical Pellets, Trimetazidine Sustained-Release Pellets, Trimetazidine Multiparticulate Pellets, and Trimetazidine Pellets for Capsule Filling can be naturally addressed through the product page's topical content.
Trimetazidine SR Pellets can be supplied in suitable pharmaceutical packaging according to the required:
Available Strength: 35% w/w, where confirmed by the applicable SDP product specification.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 1.0% |